{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:40:07Z","timestamp":1729114807922,"version":"3.27.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00393-024-01517-8","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T19:01:54Z","timestamp":1717441314000},"page":"609-619","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-Head-Therapiestudien zur rheumatoiden Arthritis","Head-to-head trials in rheumatoid arthritis"],"prefix":"10.1007","volume":"83","author":[{"given":"Diana","family":"Ernst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"1517_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld\u00a0FC, Weisman\u00a0MH, Kavanaugh\u00a0AF et\u00a0al (2006) The PREMIER study: A\u00a0multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"key":"1517_CR2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester\u00a0GR, Lin\u00a0Y, Patel\u00a0R et\u00a0al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a\u00a0randomised, double-blind, parallel-group phase\u00a0III trial. Ann Rheum Dis 76:840\u2013847","journal-title":"Ann Rheum Dis"},{"key":"1517_CR3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe\u00a0B, Kivitz\u00a0A, Tanaka\u00a0Y et\u00a0al (2021) Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a\u00a0phase\u00a0III randomised clinical trial. Ann Rheum Dis 80:848\u2013858","journal-title":"Ann Rheum Dis"},{"key":"1517_CR4","first-page":"655","volume":"39","author":"P Emery","year":"2000","unstructured":"Emery\u00a0P, Breedveld\u00a0FC, Lemmel\u00a0EM et\u00a0al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Baillieres Clin Rheumatol 39:655\u2013665","journal-title":"Baillieres Clin Rheumatol"},{"key":"1517_CR5","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery\u00a0P, Fleischmann\u00a0RM, Moreland\u00a0LW et\u00a0al (2009) Golimumab, a\u00a0human anti-tumor necrosis factor\u00a0\u03b1 monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a\u00a0phase\u00a0III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272\u20132283","journal-title":"Arthritis Rheum"},{"key":"1517_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Mysler\u00a0E, Hall\u00a0S et\u00a0al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a\u00a0phase\u00a03b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","journal-title":"Lancet"},{"key":"1517_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Schiff\u00a0M, van der Heijde\u00a0D et\u00a0al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum 69:506\u2013517","journal-title":"Arthritis Rheum"},{"key":"1517_CR8","first-page":"1786","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann\u00a0R, Pangan\u00a0AL, Song\u00a0IH et\u00a0al (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a\u00a0phase\u00a0III, double-blind, randomized controlled trial. Arthritis Rheum 71:1786\u20131800","journal-title":"Arthritis Rheum"},{"key":"1517_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay\u00a0C, Emery\u00a0P, van Vollenhoven\u00a0R et\u00a0al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a\u00a0randomised, double-blind, controlled phase\u00a04\u00a0trial. Lancet 381:1541\u20131550","journal-title":"Lancet"},{"key":"1517_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2019","unstructured":"Giles\u00a0JT, Sattar\u00a0N, Gabriel\u00a0S et\u00a0al (2019) Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A\u00a0Randomized Controlled Trial. Arthritis Rheumatol 72:31\u201340","journal-title":"Arthritis Rheumatol"},{"key":"1517_CR11","doi-asserted-by":"crossref","unstructured":"Holstiege J, Klimke K, Akmatov MK et\u00a0al Bundesweite Verordnungstrends biologischer Arzneimittel bei h\u00e4ufigen Autoimmunerkrankungen, 2012 bis 2018. www.versorgungsatlas.de\/fileadmin\/ziva_docs\/117\/VA_21-03_Bericht_Biologika_V2-2021-05-12.pdf","DOI":"10.4194\/1303-2712-v21_3_02"},{"key":"1517_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones\u00a0G, Sebba\u00a0A, Gu\u00a0J et\u00a0al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88\u201396","journal-title":"Ann Rheum Dis"},{"key":"1517_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog\u00a0L, van der Heijde\u00a0D, de Jager\u00a0JP et\u00a0al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675\u2013681","journal-title":"Lancet"},{"key":"1517_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee\u00a0EB, Fleischmann\u00a0R, Hall\u00a0S et\u00a0al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N\u00a0Engl J Med 370:2377\u20132386","journal-title":"N Engl J Med"},{"key":"1517_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M \u00d6stergaard","year":"2023","unstructured":"\u00d6stergaard\u00a0M, van Vollenhoven\u00a0RF, Rudin\u00a0A et\u00a0al (2023) Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis 82:1286\u20131295","journal-title":"Ann Rheum Dis"},{"key":"1517_CR16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth\u00a0A, Enejosa\u00a0J, Pangan\u00a0AL et\u00a0al (2020) Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N\u00a0Engl J Med 383:1511\u20131521","journal-title":"N Engl J Med"},{"key":"1517_CR17","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen\u00a0JS, Burmester\u00a0GR, Combe\u00a0B et\u00a0al (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2\u2011year efficacy and safety results from the randomised EXXELERATE study. Lancet 388:2763\u20132774","journal-title":"Lancet"},{"key":"1517_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","volume":"353","author":"JS Smolen","year":"1999","unstructured":"Smolen\u00a0JS, Kalden\u00a0JR, Scott\u00a0DL et\u00a0al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a\u00a0double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259\u2013266","journal-title":"Lancet"},{"key":"1517_CR19","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","volume":"159","author":"V Strand","year":"1999","unstructured":"Strand\u00a0V, Cohen\u00a0S, Schiff\u00a0M et\u00a0al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542\u20132550","journal-title":"Arch Intern Med"},{"key":"1517_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC, Keystone\u00a0EC, van der Heijde\u00a0D et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"1517_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/jcm8060831","volume":"8","author":"PC Taylor","year":"2019","unstructured":"Taylor\u00a0PC, Lee\u00a0YC, Fleischmann\u00a0R et\u00a0al (2019) Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J\u00a0Clin Med 8:831\u2013841","journal-title":"J Clin Med"},{"key":"1517_CR22","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R Van Vollenhoven","year":"2020","unstructured":"Van Vollenhoven\u00a0R, Takeuchi\u00a0T, Pangan\u00a0AL et\u00a0al (2020) Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A\u00a0Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. Arthritis Rheumatol 72:1607\u20131620","journal-title":"Arthritis Rheumatol"},{"key":"1517_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt\u00a0ME, Schiff\u00a0M, Valente\u00a0R et\u00a0al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a\u00a0phase\u00a0IIIb, multinational, prospective, randomized study. Arthritis Rheum 65:28\u201338","journal-title":"Arthritis Rheum"},{"key":"1517_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens\u00a0R, Rigby\u00a0WFC, van der Heijde\u00a0D et\u00a0al (2021) Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase\u00a03, randomised controlled FINCH 3\u00a0trial. Ann Rheum Dis 80:727\u2013738","journal-title":"Ann Rheum Dis"},{"key":"1517_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR et\u00a0al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N\u00a0Engl J Med 386:316\u2013326","journal-title":"N Engl J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01517-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01517-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01517-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:01:56Z","timestamp":1729112516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01517-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01517-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"22 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Ernst, K.\u00a0Kr\u00fcger und T.\u00a0Witte haben Honorare f\u00fcr Vortr\u00e4ge von folgenden Firmen erhalten: AbbVie, BMS, Chugai, Lilly, Medac, MSD, Pfizer, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}